III期非小细胞肺癌中C-12的检测及其预后意义

被引:3
作者
王伟
汪安兰
刘建国
文晓萍
机构
[1] 湖南省肿瘤医院
关键词
非小细胞肺癌; 肿瘤标志物; 多种肿瘤标志物蛋白芯片; 蛋白芯片;
D O I
暂无
中图分类号
R734.2 [肺肿瘤];
学科分类号
100214 ;
摘要
目的探讨多种肿瘤标志物蛋白芯片检测系统(C-12)在III期非小细胞肺癌的病情监测、治疗反应观察和预后评估中的意义。方法应用该芯片检测系统测定57例III期非小细胞肺癌病人化疗前后血清中12种肿瘤标志物(CA19-9,NSE,CEA,CA242,Fe,HCG,AFP,FPSA,PSA,CA125,HGH,CA15-3)的水平,观察化疗疗效与C-12的关系。结果57例病人中不同疗效组患者自身前后对照,其血清肿瘤标志物水平和C-12总阳性率无显著性差异;在剔除各组中C-12阴性病例后,PR组中的C-12阳性病人治疗后有CA19-9、CA15-3及Fe显著性降低(P<0.05),而NC组中的C-12阳性病人各项肿瘤标志物水平在化疗后均无明显变化。结论该检测系统在监测C-12阳性肺癌的治疗效果方面有一定的指导意义,如作适当改进,将能更有效地运用于临床。
引用
收藏
页码:281 / 283
页数:3
相关论文
共 11 条
[1]  
Current achievements using ProteinChip Array technology. Weinberger SR,Dalmasso EA,Fung ET. Current Opinion in Chemical Biology . 2002
[2]  
Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK im-proved sensitivity to the detection of progression in lung cancer pa-tients. Schneider J,Peltri G,Bitterlich N,et al. Anticancer Research . 2003
[3]  
The prognostic value of both neuron-specific enolase(NSE)and Cyfra21-1in small cell lung cancer. Ando S,Suzuki M,Yamamoto N,et al. Anticancer Research . 2004
[4]  
Cancer[P]. SELLAR GRANT CLARK;GABRA HANI.中国专利:US2004241682A1,2004-12-02
[5]  
Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. Ren H,Tang X,Lee JJ,et al. Journal of Clinical Oncology . 2004
[6]  
Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Ando S,Kimura H,Iwai N,et al. Anticancer Research . 2001
[7]  
The serum ferritin concentration is a sig-nificant prognostic indicator of survival in primary lung cancer. Milman N,Pedersen LM. Oncology Reports . 2002
[8]  
CYFRA21-1and CEA are independent prognostic factors in153operated stage I NSCLC pa-tients. Muley T,Dienemann H,Ebert W. Anticancer Research . 2004
[9]  
临床肿瘤内科手册[M]. 人民卫生出版社 , 孙燕,周际昌主编, 2003
[10]   多种肿瘤标志物蛋白芯片检测系统对肺癌的诊断价值 [J].
左强 ;
张军一 ;
郑航 ;
李黎波 ;
饶芬玲 ;
罗荣城 ;
李金瀚 .
中国肺癌杂志, 2004, (02) :154-157